Moleculin Consolidated Income vs Research and Development Expense Analysis

MBRX
 Stock
  

USD 1.63  0.08  4.68%   

Moleculin Biotech financial indicator trend analysis is infinitely more than just investigating Moleculin Biotech recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Moleculin Biotech is a good investment. Please check the relationship between Moleculin Biotech Consolidated Income and its Research and Development Expense accounts. Additionally, see Stocks Correlation.

Consolidated Income vs Research and Development Expense

Consolidated Income vs Research and Development Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Moleculin Biotech Consolidated Income account and Research and Development Expense. At this time, the significance of the direction appears to have pay attention.
The correlation between Moleculin Biotech's Consolidated Income and Research and Development Expense is -0.98. Overlapping area represents the amount of variation of Consolidated Income that can explain the historical movement of Research and Development Expense in the same time period over historical financial statements of Moleculin Biotech CS, assuming nothing else is changed. The correlation between historical values of Moleculin Biotech's Consolidated Income and Research and Development Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Consolidated Income of Moleculin Biotech CS are associated (or correlated) with its Research and Development Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research and Development Expense has no effect on the direction of Consolidated Income i.e., Moleculin Biotech's Consolidated Income and Research and Development Expense go up and down completely randomly.

Correlation Coefficient

-0.98
Relationship DirectionNegative 
Relationship StrengthSignificant

Consolidated Income

The portion of profit or loss for the period; net of income taxes; which is attributable to the consolidated entity; before the deduction of Net Income Available to Non-controlling Interests.

Research and Development Expense

A component of Operating Expenses representing the aggregate costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service.
Most indicators from Moleculin Biotech fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Moleculin Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Additionally, see Stocks Correlation.Moleculin Biotech Issuance Purchase of Equity Shares is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Issuance Purchase of Equity Shares of 74.75 Million in 2021. Enterprise Value over EBIT is likely to rise to 1.08 in 2022, whereas Selling General and Administrative Expense is likely to drop slightly above 6.9 M in 2022.

Moleculin Biotech fundamental ratios Correlations

0.340.940.980.350.98-0.44-0.44-0.420.96-1.00.130.51-0.110.260.37-1.0
0.340.60.490.750.47-0.76-0.86-0.740.55-0.340.680.820.490.640.83-0.34
0.940.60.990.590.98-0.67-0.71-0.651.0-0.940.360.70.10.360.61-0.94
0.980.490.990.481.0-0.57-0.59-0.550.99-0.980.30.630.050.340.53-0.98
0.350.750.590.480.47-0.99-0.86-1.00.57-0.350.360.560.190.060.64-0.35
0.980.470.981.00.47-0.56-0.58-0.540.99-0.980.270.620.020.320.51-0.98
-0.44-0.76-0.67-0.57-0.99-0.560.91.0-0.650.44-0.38-0.61-0.2-0.09-0.670.44
-0.44-0.86-0.71-0.59-0.86-0.580.90.87-0.680.45-0.5-0.77-0.28-0.3-0.720.45
-0.42-0.74-0.65-0.55-1.0-0.541.00.87-0.630.42-0.35-0.57-0.18-0.05-0.640.42
0.960.551.00.990.570.99-0.65-0.68-0.63-0.960.270.650.010.30.53-0.96
-1.0-0.34-0.94-0.98-0.35-0.980.440.450.42-0.96-0.13-0.510.11-0.26-0.371.0
0.130.680.360.30.360.27-0.38-0.5-0.350.27-0.130.710.940.730.91-0.13
0.510.820.70.630.560.62-0.61-0.77-0.570.65-0.510.710.440.740.87-0.51
-0.110.490.10.050.190.02-0.2-0.28-0.180.010.110.940.440.580.750.11
0.260.640.360.340.060.32-0.09-0.3-0.050.3-0.260.730.740.580.66-0.26
0.370.830.610.530.640.51-0.67-0.72-0.640.53-0.370.910.870.750.66-0.37
-1.0-0.34-0.94-0.98-0.35-0.980.440.450.42-0.961.0-0.13-0.510.11-0.26-0.37
Click cells to compare fundamentals

Moleculin Biotech Account Relationship Matchups

Moleculin Biotech fundamental ratios Accounts

201720182019202020212022 (projected)
Accounts Payable810 K1.25 M2.15 M1.13 M1.36 M1.2 M
Total Assets19.48 M19.59 M25.23 M29.03 M84.09 M90.73 M
Current Assets8.3 M7.97 M13.48 M17.2 M72.5 M78.22 M
Assets Non Current11.18 M11.61 M11.75 M11.83 M11.59 M11.84 M
Cash and Equivalents7.71 M7.13 M10.73 M15.17 M70.9 M76.5 M
Cash and Equivalents USD7.71 M7.13 M10.73 M15.17 M70.9 M76.5 M
Total Debt450 K296 K276 K159 K63 K64.66 K
Total Debt USD450 K296 K276 K159 K63 K64.66 K
Shareholders Equity17.12 M14.27 M15.57 M17.76 M78.99 M85.23 M
Shareholders Equity USD17.12 M14.27 M15.57 M17.76 M78.99 M85.23 M
Total Liabilities2.37 M5.31 M9.66 M11.27 M5.1 M5.52 M
Current Liabilities2.21 M3.88 M3.57 M2.92 M3.62 M3.35 M
Liabilities Non Current150 K1.44 M6.09 M8.35 M1.48 M1.51 M
Trade and Non Trade Payables810 K1.25 M2.15 M1.13 M1.36 M1.33 M
Property Plant and Equipment Net33 K463 K603 K685 K445 K422.33 K
Accumulated Retained Earnings Deficit(14.48 M)(26.36 M)(39.56 M)(56.92 M)(72.81 M)(74.73 M)

Moleculin Biotech Investors Sentiment

The influence of Moleculin Biotech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Moleculin. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moleculin Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moleculin Biotech's short interest history, or implied volatility extrapolated from Moleculin Biotech options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moleculin Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
48 M
Return On Assets
-0.17
Return On Equity
-0.23
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.